Bio-Techne

-4.09%

More reviews (1)

Live  

Bio-Techne is a global life sciences company that provides innovative research tools and solutions to scientists and clinicians. The company was established in 1976 and is headquartered in Minneapolis, Minnesota. It operates through four key divisions: Bio-Techne, R&D Systems, Novus Biologicals, and ProteinSimple.
Bio-Techne's products include proteins, antibodies, assays, and reagents for a wide range of research areas such as cell biology, immunology, neuroscience, and drug discovery. The company also offers services such as protein analysis, contract manufacturing, and custom antibody development.
Bio-Techne has a strong global presence, with offices and distribution centers in North America, Europe, and Asia-Pacific. It serves customers in over 160 countries and has collaborations with leading pharmaceutical and biotech companies.
The company is committed to advancing science and improving human health through its products and services. It invests heavily in research and development to continuously innovate and expand its product portfolio. Bio-Techne also supports the scientific community through educational initiatives and partnerships with academic institutions.
In addition to its research tools and solutions, Bio-Techne has a strong focus on corporate social responsibility and sustainability. It has implemented various initiatives to reduce its environmental impact and support the communities where it operates.
Overall, Bio-Techne is a leading company in the life sciences industry, known for its high-quality products, scientific expertise, and commitment to improving human health.

Bio-Techne is a company that makes special tools and products for scientists and researchers who study living things, like cells and proteins. Think of them like a big toolbox full of gadgets that help scientists learn more about diseases, how our bodies work, and even how to create new medicines.
The way Bio-Techne makes money is by selling these products to universities, hospitals, and companies that do research. They have things like proteins, antibodies (which help scientists find and study other proteins), and machines that help measure and analyze different biological samples. Whenever researchers need these tools, they buy them from Bio-Techne.
Bio-Techne is successful because they make high-quality products that scientists trust. If scientists can rely on their tools, they’ll keep coming back to buy more, and that helps the company earn money. They are also always looking for new and better ways to help researchers, which keeps them ahead of the competition.
In the future, Bio-Techne is likely to stay successful because science and research are always advancing. There will always be new discoveries to make and diseases to study, which means a continued need for their products. Plus, as technology gets better, they can create even more innovative tools that will help scientists work more efficiently, leading to more sales and growth. So, as long as there is curiosity about life and how it works, Bio-Techne will be there, helping scientists along the way!

MS4gUmVub3 duZWQgQmlv dGVjaCBDb2 1wYW55OiBC aW8tVGVjaG 5lIGlzIGEg Z2xvYmFsbH kgcmVjb2du aXplZCBiaW 90ZWNoIGNv bXBhbnkgdG hhdCBzcGVj aWFsaXplcy BpbiBwcm92 aWRpbmcgaW 5ub3ZhdGl2 ZSBzb2x1dG lvbnMgZm9y IGxpZmUgc2 NpZW5jZSBy ZXNlYXJjaC wgZGlhZ25v c3RpY3MsIG FuZCBjbGlu aWNhbCBsYW JvcmF0b3Jp ZXMuPGJyPj IuIERpdmVy c2UgUHJvZH VjdCBQb3J0 Zm9saW86IF RoZSBjb21w YW55IG9mZm VycyBhIGRp dmVyc2Ugcm FuZ2Ugb2Yg aGlnaC1xdW FsaXR5IHBy b2R1Y3RzIG luY2x1ZGlu ZyBhbnRpYm 9kaWVzLCBw cm90ZWlucy wgYXNzYXlz LCBmbG93IG N5dG9tZXRy eSwgaW1hZ2 luZywgYW5k IG1vbGVjdW xhciBiaW9s b2d5IHJlYW dlbnRzLiBU aGlzIGV4dG Vuc2l2ZSBw cm9kdWN0IH BvcnRmb2xp byBhbGxvd3 MgcmVzZWFy Y2hlcnMgYW 5kIGNsaW5p Y2lhbnMgdG 8gYWNjZXNz IGFsbCB0aG UgbmVjZXNz YXJ5IHRvb2 xzIGZvciB0 aGVpciB3b3 JrLjxicj4z LiBDdXR0aW 5nLWVkZ2Ug VGVjaG5vbG 9neTogQmlv LVRlY2huZS B1dGlsaXpl cyBjdXR0aW 5nLWVkZ2Ug dGVjaG5vbG 9neSB0byBk ZXZlbG9wIG FuZCBtYW51 ZmFjdHVyZS BpdHMgcHJv ZHVjdHMuIF RoaXMgaW5j bHVkZXMgYW R2YW5jZWQg cHJvdGVpbi BhbmQgYW50 aWJvZHkgZW 5naW5lZXJp bmcgcGxhdG Zvcm1zLCBm bG93IGN5dG 9tZXRyeSBh bmQgaW1hZ2 luZyBzeXN0 ZW1zLCBhbm QgbW9sZWN1 bGFyIGFuZC BjZWxsIGJp b2xvZ3kgdG VjaG5pcXVl cy48YnI+NC 4gRXhwZXJ0 aXNlIGluIE 11bHRpcGxl IERpc2NpcG xpbmVzOiBC aW8tVGVjaG 5lIGhhcyBl eHBlcnRpc2 UgaW4gbXVs dGlwbGUgZG lzY2lwbGlu ZXMgc3VjaC BhcyBpbW11 bm9sb2d5LC BjZWxsIGJp b2xvZ3ksIG 5ldXJvc2Np ZW5jZSwgYW 5kIG1vbGVj dWxhciBkaW Fnbm9zdGlj cy4gVGhpcy BhbGxvd3Mg dGhlIGNvbX BhbnkgdG8g cHJvdmlkZS Bjb21wcmVo ZW5zaXZlIH NvbHV0aW9u cyBmb3IgYS B3aWRlIHJh bmdlIG9mIH Jlc2VhcmNo IGFyZWFzLj xicj41LiBH bG9iYWwgUm VhY2g6IFdp dGggaGVhZH F1YXJ0ZXJz IGluIHRoZS BVbml0ZWQg U3RhdGVzLC BCaW8tVGVj aG5lIGhhcy BhIGdsb2Jh bCBwcmVzZW 5jZSB3aXRo IG1hbnVmYW N0dXJpbmcg ZmFjaWxpdG llcywgZGlz dHJpYnV0aW 9uIGNlbnRl cnMsIGFuZC BzYWxlcyBv ZmZpY2VzIG luIG11bHRp cGxlIGNvdW 50cmllcy4g VGhpcyBlbm FibGVzIHRo ZSBjb21wYW 55IHRvIHNl cnZlIGN1c3 RvbWVycyBh bGwgb3Zlci B0aGUgd29y bGQuPGJyPj YuIFN0cm9u ZyBTY2llbn RpZmljIENv bGxhYm9yYX Rpb25zOiBU aGUgY29tcG FueSBoYXMg c3Ryb25nIG NvbGxhYm9y YXRpb25zIH dpdGggbGVh ZGluZyBhY2 FkZW1pYyBh bmQgcmVzZW FyY2ggaW5z dGl0dXRpb2 5zLCB3aGlj aCBhbGxvd3 MgdGhlbSB0 byBzdGF5IG F0IHRoZSBm b3JlZnJvbn Qgb2Ygc2Np ZW50aWZpYy BhZHZhbmNl bWVudHMgYW 5kIGRldmVs b3AgbmV3IH Byb2R1Y3Rz Ljxicj43Li BDb21taXRt ZW50IHRvIF F1YWxpdHkg YW5kIFNhZm V0eTogQmlv LVRlY2huZS BoYXMgYSBz dHJpY3QgcX VhbGl0eSBj b250cm9sIH N5c3RlbSBp biBwbGFjZS B0byBlbnN1 cmUgdGhlIH NhZmV0eSBh bmQgZWZmZW N0aXZlbmVz cyBvZiBpdH MgcHJvZHVj dHMuIFRoZX kgaGF2ZSBv YnRhaW5lZC BJU08gMTM0 ODUgY2VydG lmaWNhdGlv biBhbmQgYX JlIGNvbXBs aWFudCB3aX RoIEZEQSBy ZWd1bGF0aW 9ucy48YnI+ OC4gRm9jdX Mgb24gQ3Vz dG9tZXIgU2 VydmljZTog VGhlIGNvbX BhbnkgaGFz IGEgY3VzdG 9tZXItY2Vu dHJpYyBhcH Byb2FjaCBh bmQgaXMgY2 9tbWl0dGVk IHRvIHByb3 ZpZGluZyBl eGNlcHRpb2 5hbCBjdXN0 b21lciBzZX J2aWNlLiBU aGV5IG9mZm VyIHRlY2hu aWNhbCBzdX Bwb3J0LCB0 cmFpbmluZy wgYW5kIGN1 c3RvbWl6ZW Qgc29sdXRp b25zIHRvIG 1lZXQgdGhl IHVuaXF1ZS BuZWVkcyBv ZiB0aGVpci BjdXN0b21l cnMu

VGhlIEJpby 1UZWNobmUg Y29tcGFueS dzIGJ1c2lu ZXNzIG1vZG VsIGlzIGZv Y3VzZWQgb2 4gZGV2ZWxv cGluZywgbW FudWZhY3R1 cmluZywgYW 5kIGRpc3Ry aWJ1dGluZy BoaWdoLXF1 YWxpdHkgbG lmZSBzY2ll bmNlIHJlYW dlbnRzIGFu ZCBpbnN0cn VtZW50cyB1 c2VkIGluIG Jpb21lZGlj YWwgcmVzZW FyY2ggYW5k IGNsaW5pY2 FsIGRpYWdu b3N0aWNzLi BUaGlzIGlu Y2x1ZGVzIH Byb2R1Y3Rz IHN1Y2ggYX MgYW50aWJv ZGllcywgcH JvdGVpbnMs IGFzc2F5IG tpdHMsIGFu ZCBpbnN0cn VtZW50cyBm b3IgY2VsbC BhbmQgZ2Vu ZSB0aGVyYX B5LCBpbW11 bm90aGVyYX B5LCBhbmQg bW9sZWN1bG FyIGRpYWdu b3N0aWNzLi BCaW8tVGVj aG5lIHNlbG xzIGl0cyBw cm9kdWN0cy BkaXJlY3Rs eSB0byBjdX N0b21lcnMs IGFzIHdlbG wgYXMgdGhy b3VnaCBkaX N0cmlidXRv cnMgYW5kIE 9FTSAob3Jp Z2luYWwgZX F1aXBtZW50 IG1hbnVmYW N0dXJlcikg cGFydG5lcn NoaXBzLiBU aGUgY29tcG FueSBhbHNv IHByb3ZpZG VzIGNvbnRy YWN0IHJlc2 VhcmNoIGFu ZCBtYW51Zm FjdHVyaW5n IHNlcnZpY2 VzIGZvciB0 aGUgZGV2ZW xvcG1lbnQg YW5kIHByb2 R1Y3Rpb24g b2YgY3VzdG 9tIHJlYWdl bnRzIGFuZC Bhc3NheXMu IEFkZGl0aW 9uYWxseSwg QmlvLVRlY2 huZSBoYXMg c3RyYXRlZ2 ljIGFsbGlh bmNlcyBhbm QgY29sbGFi b3JhdGlvbn Mgd2l0aCBv dGhlciBjb2 1wYW5pZXMg YW5kIG9yZ2 FuaXphdGlv bnMgdG8gYW R2YW5jZSBy ZXNlYXJjaC BhbmQgaW5u b3ZhdGlvbi BpbiB0aGUg bGlmZSBzY2 llbmNlcyBm aWVsZC4=

AI can pose several potential threats to a biotech company like Bio-Techne, particularly in the areas of substitution, disintermediation, and margin pressure.
1. Substitution: AI and advanced computational techniques can lead to the development of new methods for data analysis and interpretation in life sciences, which may substitute some of the traditional products and services that Bio-Techne offers. For instance, AI-driven platforms for drug discovery and personalized medicine can reduce the reliance on existing tools and reagents produced by Bio-Techne, affecting demand.
2. Disintermediation: AI can enable researchers and clinicians to access information and perform analyses directly without the need for intermediaries. With AI tools that allow for idepth genomic analysis or protein characterization, customers may opt to conduct their experiments ihouse, reducing their dependency on Bio-Techne’s products or services.
3. Margin Pressure: The integration of AI into biotech can lead to increased competition and a drive for cost efficiency. Companies utilizing AI technologies may be able to offer similar products at lower prices, pressuring traditional firms like Bio-Techne to lower their margins. As AI tools become more widespread and accessible, Bio-Techne may need to innovate or invest heavily in AI capabilities to remain competitive, which can impact profit margins.
In conclusion, while AI does pose potential threats in these areas, it also offers opportunities for innovation and enhancement of existing products and services. How Bio-Techne navigates these challenges will play a critical role in its ongoing competitive positioning.

The sensitivity of Bio-Techne’s earnings, cash flow, and valuation to changes in interest rates can be understood through several key factors:
1. Cost of Capital: As interest rates increase, the cost of borrowing also rises. This can impact Bio-Techne’s ability to finance new projects, acquisitions, or research and development through debt, potentially leading to higher costs and reduced profitability.
2. Discount Rate: Higher interest rates often lead to a higher discount rate applied to future cash flows in valuation models. For a company like Bio-Techne, which may expect growth in earnings and cash flows over time, a higher discount rate can significantly reduce the present value of these cash flows, leading to lower valuations.
3. Market Sentiment: Rising interest rates can affect investor sentiment and risk appetite. As rates go up, equities may be seen as less attractive compared to fixed-income investments, which could result in selling pressure on Bio-Techne’s stock, thus impacting its market valuation.
4. Impact on Revenue Growth: If interest rates lead to broader economic slowdowns, spending on biotechnology and life sciences products and services may tighten for customers, impacting Bio-Techne’s revenue growth.
5. Operational Costs: Higher interest rates can also lead to increased operational costs if the company has existing variable-rate debt. This could further squeeze margins and cash flow.
In summary, while Bio-Techne’s specific sensitivity to interest rate changes would depend on its financial structure, current debt levels, and operational strategy, the general implications of rising rates could lead to diminished earnings, strained cash flows, and a lower overall valuation.

CiAgICAgIC AgICAgIDxk aXYgc3R5bG U9J3dpZHRo OiAxMDAlOy BkaXNwbGF5 OiBmbGV4Oy BqdXN0aWZ5 LWNvbnRlbn Q6IGNlbnRl cjsnPgogIC AgICAgICAg ICAgICAgPG RpdiBzdHls ZT0nCiAgIC AgICAgICAg ICAgICAgIC AgZGlzcGxh eTogZmxleD sKICAgICAg ICAgICAgIC AgICAgICBh bGlnbi1pdG VtczogY2Vu dGVyOwogIC AgICAgICAg ICAgICAgIC AgIGJhY2tn cm91bmQtY2 9sb3I6ICNm MGY0Zjg7Ci AgICAgICAg ICAgICAgIC AgICAgYm9y ZGVyOiAxcH ggc29saWQg I2QxZTNmMD sKICAgICAg ICAgICAgIC AgICAgICBi b3JkZXItcm FkaXVzOiAx MHB4OwogIC AgICAgICAg ICAgICAgIC AgIHBhZGRp bmc6IDEwcH g7CiAgICAg ICAgICAgIC AgICAgICAg bWFyZ2luOi AyMHB4IDA7 CiAgICAgIC AgICAgICAg ICAgICAgZm 9udC1mYW1p bHk6ICJTZW dvZSBVSSIs IFJvYm90by wgc2Fucy1z ZXJpZjsKIC AgICAgICAg ICAgICAgIC AgICBib3gt c2hhZG93Oi AwIDJweCA2 cHggcmdiYS gwLCAwLCAw LCAwLjA1KT sKICAgICAg ICAgICAgIC AgICAgICBt YXgtd2lkdG g6IDkwMHB4 OwogICAgIC AgICAgICAg ICAgICAgIH dpZHRoOiAx MDAlOyc+Cg ogICAgICAg ICAgICAgIC AgICAgIDxp bWcgc3JjPS Jhc3NldHMv bG9nb3MvUn BJYjlQcHBR b2wzQ1VVN3 FMMkIud2Vi cCIgYWx0PS JCaW8tVGVj aG5lIiB0aX RsZT0iQmlv LVRlY2huZS IgIGNsYXNz PSJpbWctZm x1aWQiIGhl aWdodD05MC B3aWR0aD05 MCBsb2FkaW 5nPSdsYXp5 JyBzdHlsZT 0nYm9yZGVy LXJhZGl1cz ogNnB4Oyc+ CgogICAgIC AgICAgICAg ICAgICAgID xkaXYgc3R5 bGU9J2ZsZX g6IDE7IHRl eHQtYWxpZ2 46IGNlbnRl cjsgbWFyZ2 luLWxlZnQ6 IDVweDsnPg ogICAgICAg ICAgICAgIC AgICAgICAg ICA8cCBzdH lsZT0nZm9u dC1zaXplOi AyNnB4OyBj b2xvcjogIz MzMzsgbWFy Z2luLWJvdH RvbTogMTVw eDsnPgogIC AgICAgICAg ICAgICAgIC AgICAgICAg ICAg8J+TiC BXYW50IHRv IHJlYWQgbW 9yZSBhYm91 dCBCaW8tVG VjaG5lPwog ICAgICAgIC AgICAgICAg ICAgICAgIC A8L3A+Cgog ICAgICAgIC AgICAgICAg ICAgICAgIC A8YSBocmVm PSdpbmRleC 5waHA/cGFn ZT1zaWdudX AnIHN0eWxl PScKICAgIC AgICAgICAg ICAgICAgIC AgICAgICAg IGJhY2tncm 91bmQtY29s b3I6ICMwMD dCRkY7CiAg ICAgICAgIC AgICAgICAg ICAgICAgIC AgICBjb2xv cjogI2ZmZj sKICAgICAg ICAgICAgIC AgICAgICAg ICAgICAgIH BhZGRpbmc6 IDEwcHggMj BweDsKICAg ICAgICAgIC AgICAgICAg ICAgICAgIC AgIGJvcmRl ci1yYWRpdX M6IDVweDsK ICAgICAgIC AgICAgICAg ICAgICAgIC AgICAgIHRl eHQtZGVjb3 JhdGlvbjog bm9uZTsKIC AgICAgICAg ICAgICAgIC AgICAgICAg ICAgIGZvbn Qtd2VpZ2h0 OiBib2xkOw ogICAgICAg ICAgICAgIC AgICAgICAg ICAgICAgbW FyZ2luLXJp Z2h0OiAxMH B4OwogICAg ICAgICAgIC AgICAgICAg ICAgICAgIC AgdHJhbnNp dGlvbjogYm Fja2dyb3Vu ZC1jb2xvci AwLjNzIGVh c2U7JwogIC AgICAgICAg ICAgICAgIC AgICAgICAg ICAgb25tb3 VzZW92ZXI9 J3RoaXMuc3 R5bGUuYmFj a2dyb3VuZE NvbG9yPSIj MDA1NmIzIi cKICAgICAg ICAgICAgIC AgICAgICAg ICAgICAgIG 9ubW91c2Vv dXQ9J3RoaX Muc3R5bGUu YmFja2dyb3 VuZENvbG9y PSIjMDA3Qk ZGIic+CiAg ICAgICAgIC AgICAgICAg ICAgICAgIC AgICBTaWdu IHVwIGZvci BmcmVlCiAg ICAgICAgIC AgICAgICAg ICAgICAgID wvYT4KCiAg ICAgICAgIC AgICAgICAg ICAgICAgID xzcGFuIHN0 eWxlPSdtYX JnaW46IDAg OHB4OyBjb2 xvcjogIzU1 NTsnPm9yPC 9zcGFuPgoK ICAgICAgIC AgICAgICAg ICAgICAgIC AgPGEgaHJl Zj0naW5kZX gucGhwP3Bh Z2U9bG9naW 4nIHN0eWxl PScKICAgIC AgICAgICAg ICAgICAgIC AgICAgICAg IGNvbG9yOi AjMDA3QkZG OwogICAgIC AgICAgICAg ICAgICAgIC AgICAgICAg dGV4dC1kZW NvcmF0aW9u OiB1bmRlcm xpbmU7CiAg ICAgICAgIC AgICAgICAg ICAgICAgIC AgICBmb250 LXdlaWdodD ogNTAwOyc+ CiAgICAgIC AgICAgICAg ICAgICAgIC AgICAgICBs b2cgaW4KIC AgICAgICAg ICAgICAgIC AgICAgICAg PC9hPgoKCi AgICAgICAg ICAgICAgIC AgICAgICAg IDxwIHN0eW xlPSdtYXJn aW4tdG9wOi AxNXB4OyBm b250LXNpem U6IDEzcHg7 IGZvbnQtd2 VpZ2h0OiBi b2xkOyBjb2 xvcjogI2Qz MmYyZjsnPg ogICAgICAg ICAgICAgIC AgICAgICAg ICAgICAg4p qhIEluc3Rh bnRseSBhY2 Nlc3MgPGk+ IlRoZSBDaG Vja2xpc3Qg VmFsdWUgSW 52ZXN0b3Ig 4oCUIEEgU2 1hcnRlciBX YXkgdG8gUG ljayBTdG9j a3MiPC9pPi DigJQgZnJl ZSEKICAgIC AgICAgICAg ICAgICAgIC AgICAgPC9w PgoKICAgIC AgICAgICAg ICAgICAgIC AgICAgPCEt LQogICAgIC AgICAgICAg ICAgICAgIC AgICA8ZGl2 IHN0eWxlPS dtYXJnaW4t dG9wOiAxMn B4OyBmb250 LXNpemU6ID EzcHg7IGNv bG9yOiAjND Q0Oyc+CiAg ICAgICAgIC AgICAgICAg ICAgICAgIC AgICBTaWdu IHVwIG5vdy BhbmQgZ2V0 IG91ciBmcm VlIGVCb29r IAogICAgIC AgICAgICAg ICAgICAgIC AgICAgICAg PGI+VGhlIE NoZWNrbGlz dCBWYWx1ZS BJbnZlc3Rv ciDigJQgQS BTbWFydGVy IFdheSB0by BQaWNrIFN0 b2NrczwvYj 4KICAgICAg ICAgICAgIC AgICAgICAg ICAgPC9kaX Y+CiAgICAg ICAgICAgIC AgICAgICAg ICAgIC0tPg ogICAgICAg ICAgICAgIC AgICAgICAg ICA8IS0tCi AgICAgICAg ICAgICAgIC AgICAgICAg IDxkaXYgc3 R5bGU9J21h cmdpbi10b3 A6IDE2cHg7 IGZvbnQtc2 l6ZTogMTRw eDsgY29sb3 I6ICM0NDQ7 IGZvbnQtZm FtaWx5OiAt YXBwbGUtc3 lzdGVtLCBC bGlua01hY1 N5c3RlbUZv bnQsIFNlZ2 9lIFVJLCBS b2JvdG8sIE hlbHZldGlj YSBOZXVlLC BzYW5zLXNl cmlmOyBsaW 5lLWhlaWdo dDogMS42Oy c+CiAgICAg ICAgICAgIC AgICAgICAg ICAgICAgIC BIYXZlIHlv dSBoZWFyZC BhYm91dCBv dXIgc2hvcn QgPHN0cm9u ZyBzdHlsZT 0nZm9udC13 ZWlnaHQ6ID YwMDsnPkRh aWx5IFZpZG VvIE5ld3Ns ZXR0ZXI8L3 N0cm9uZz4/ CiAgICAgIC AgICAgICAg ICAgICAgIC AgICAgICA8 YSBocmVmPS dodHRwczov L3d3dy5pbn NpZ2h0ZnVs dmFsdWUuY2 9tL25ld3Ns ZXR0ZXIucG hwJyB0YXJn ZXQ9J19ibG Fuaycgc3R5 bGU9J2NvbG 9yOiAjMDA3 QkZGOyB0ZX h0LWRlY29y YXRpb246IG 5vbmU7IGZv bnQtd2VpZ2 h0OiA1MDA7 IG1hcmdpbi 1sZWZ0OiA2 cHg7Jz4KIC AgICAgICAg ICAgICAgIC AgICAgICAg ICAgICAgIC BGaW5kIG91 dCBtb3JlCi AgICAgICAg ICAgICAgIC AgICAgICAg ICAgICA8L2 E+CiAgICAg ICAgICAgIC AgICAgICAg ICAgIDwvZG l2PgogICAg ICAgICAgIC AgICAgICAg ICAgICAtLT 4KICAgICAg ICAgICAgIC AgICAgICA8 L2Rpdj4KIC AgICAgICAg ICAgICAgID wvZGl2Pgog ICAgICAgIC AgICA8L2Rp dj4KICAgIC AgICAgICAg CiAgICAgIC AgCiAgICAg ICAgPHNwYW 4gY2xhc3M9 J2JsdXJyZW QtdGV4dCc+ CiAgICAgIC AgICAgIE1T NGdRbWx2TF YgUmxZMmh1 WlNCRCBiM0 p3YjNKaGRH IGx2YmlCM1 lYTWcgWm05 MWJtUmxaQy BCcGJpQXhP VGMyIElHRn VaQ0IzWVgg TWdiM0pwWj JsdSBZV3hz ZVNCcmJtID kzYmlCaGN5 QlUgWldOb2 JtVWdRMiA5 eWNHOXlZWF JwIGIyNHVQ R0p5UGogSX VJRlJvWlNC aiBiMjF3WV c1NUlIIE4w WVhKMFpXUW cgWVhNZ1lT QnRZVyA1MV ptRmpkSFZ5 IFpYSWdiMl lnYVcgNXpk SEoxYldWdS BkSE1nZFhO bFpDIEJtYj NJZ2FXMXQg ZFc1dlpHbG haMiA1dmMz UnBZM01zIE lITndaV05w Wm0gbGpZV3 hzZVNCbSBi M0lnYldWaG MzIFZ5YVc1 bklHTjUgZE c5cmFXNWxj eSBCaGJtUW dhVzUwIFpY Sm1aWEp2Ym 4gTXVJRHhp Y2o0eiBMaU JKYmlBeE9U IGs1TENCMG FHVWcgWTI5 dGNHRnVlUy BCaFkzRjFh WEpsIFpDQl NKa1FnVTMg bHpkR1Z0Y3 l3ZyBZU0Jz WldGa2FXID VuSUhOMWNI QnMgYVdWeU lHOW1JSCBC eWIzUmxhVz V6IExDQmhi blJwWW0gOW thV1Z6TENC aCBibVFnYV cxdGRXIDV2 WVhOellYa2 cgY0hKdlpI VmpkSCBNdU lGUm9hWE1n IFlXTnhkV2 x6YVggUnBi MjRnYldGeS BhMlZrSUhS b1pTIEJpWl dkcGJtNXAg Ym1jZ2IyWW dRbSBsdkxW UmxZMmh1IF plS0FtWE1n WlggaHdZVz V6YVc5dSBJ R2x1ZEc4Z2 RHIGhsSUd4 cFptVWcgYz JOcFpXNWpa WCBNZ2JXRn lhMlYwIExq eGljajQwTG kgQkNhVzh0 VkdWaiBhRz VsSUdoaGN5 IEJoSUdkc2 IySmggYkNC d2NtVnpaVy A1alpTd2dk MmwwIGFDQn ZjR1Z5WVgg UnBiMjV6SU dsdSBJRzky WlhJZ05UIE FnWTI5MWJu UnkgYVdWek lHRnVaQyBC amRYTjBiMj FsIGNuTWdh VzRnYjMgWm xjaUF4TXpV ZyBZMjkxYm 5SeWFXIFZ6 TGp4aWNqND EgTGlCVWFH VWdZMiA5dG NHRnVlZUtB IG1YTWdjSE p2WkggVmpk SE1nWVhKbC BJSFZ6WldR Z2FXIDRnZG 1GeWFXOTEg Y3lCbWFXVn NaSCBNZ2Mz VmphQ0JoIG N5QnRaV1Jw WTIgRnNJSE psYzJWaCBj bU5vTENCa2 NuIFZuSUdS bGRtVnMgYj NCdFpXNTBM QyBCaGJtUW daR2xoIFoy NXZjM1JwWT MgTXVQR0p5 UGpZdSBJRU pwYnkxVVpX IE5vYm1YaW dKbHogSUdo bFlXUnhkVy BGeWRHVnlj eUJoIGNtVW diRzlqWVgg UmxaQ0JwYm lCTiBhVzV1 WldGd2IyIH hwY3l3Z1RX bHUgYm1Wem IzUmhMQyBC aGJtUWdhWF FnIGFHRnpJ RzFoYm4gVm 1ZV04wZFhK cCBibWNnWm 1GamFXIHhw ZEdsbGN5Qn AgYmlCMGFH VWdWVyA1cG RHVmtJRk4w IFlYUmxjeX dnUTIgRnVZ V1JoTENCRC BhR2x1WVN3 Z1lXIDVrSU VWMWNtOXcg WlM0OFluSS tOeSA0Z1ZH aGxJR052IG JYQmhibmtn YUcgRnpJRz kyWlhJZyBN eXc0TURBZ1 pXIDF3Ykc5 NVpXVnogSU hkdmNteGtk MiBsa1pTND hZbkkrIE9D NGdTVzRnTW ogQXlNQ3dn UW1sdiBMVl JsWTJodVpT IEIzWVhNZ2 JtRnQgWldR Z2IyNWxJRy A5bUlIUm9a U0JYIGIzSn NaT0tBbVgg TWdUVzl6ZE NCSiBibTV2 ZG1GMGFYIF psSUVOdmJY QmggYm1sbG N5QmllUyBC R2IzSmlaWE 1nIGJXRm5Z WHBwYm0gVX VQR0p5UGpr dSBJRlJvWl NCamIyIDF3 WVc1NUlHbH ogSUd4cGMz UmxaQyBCdm JpQjBhR1Vn IFRrRlRSRU ZSSUggTjBi Mk5ySUdWNC BZMmhoYm1k bElIIFZ1Wk dWeUlIUm8g WlNCMGFXTn JaWCBJZ2Mz bHRZbTlzIE lGUkZRMGd1 UEcgSnlQak V3TGlCQyBh Vzh0VkdWam FHIDVsSUds eklHTnYgYl cxcGRIUmxa QyBCMGJ5Qn pkWE4wIFlX bHVZV0pwYk cgbDBlU0Jo Ym1RZyBhR0 Z6SUhKbFpI IFZqWldRZ2 FYUnogSUdO aGNtSnZiaS BCbGJXbHpj Mmx2IGJuTW dZbmtnTnog QWxJSE5wYm 1ObCBJREl3 TVRVdUlFIG wwSUdGc2My OGcgYUdGek lHRWdjSCBK dlozSmhiU0 JwIGJpQndi R0ZqWlMgQj BieUJ5WldS MSBZMlVnYz JsdVoyIHhs TFhWelpTQn cgYkdGemRH bGpJRyBsdU lHbDBjeUJ3 IGNtOWtkV0 4wY3kgQmhi bVFnY0dGai BhMkZuYVc1 bkxqIHhpY2 o0eE1TNGcg U1c0Z1lXUm thWCBScGIy NGdkRzhnIG FYUnpJRzFo YVcgNGdZWE psWVhNZyBi MllnWm05am RYIE1zSUVK cGJ5MVUgWl dOb2JtVWdZ VyB4emJ5Qn ZabVpsIGNu TWdZM1Z6ZE cgOXRJRzFo Ym5WbSBZV0 4wZFhKcGJt IGNnYzJWeW RtbGogWlhN Z1ptOXlJRy BOMWMzUnZi V1Z5IGN5Qn BiaUIwYUcg VWdZbWx2ZE dWaiBhQ0Jw Ym1SMWMzIF J5ZVM0OFlu SSsgTVRJdU lGUm9aUyBC amIyMXdZVz U1IElHaGhj eUJ5WlcgTm xhWFpsWkNC dCBkV3gwYV hCc1pTIEJo ZDJGeVpITW cgWVc1a0lI SmxZMiA5bm JtbDBhVzl1 IElHWnZjaU JwZEggTWdj SEp2WkhWai BkSE1nWVc1 a0lIIE5sY2 5acFkyVnog TENCcGJtTn NkVyBScGJt Y2dkR2hsIE lFTnBkR1ZC WWkgQmhkMk Z5WkNCbSBi M0lnUW1Wem RDIEJCYm5S cFltOWsgZV NCVGRYQndi RyBsbGNpQm hibVFnIGRH aGxJRk5qYV cgVnVkR2x6 ZEhQaSBnSm tnUTJodmFX IE5sSUVGM1 lYSmsgSUda dmNpQkNaWC BOMElFNWxk eUJNIGFXWm xJRk5qYVcg VnVZMlZ6SU ZCeSBiMlIx WTNRdVBHIE p5UGpFekxp QkMgYVc4dF ZHVmphRyA1 bElHbHpJR2 x1IGRtOXNk bVZrSUcgbH VJSFpoY21s diBkWE1nY0 docGJHIEZ1 ZEdoeWIzQn AgWXlCbFpt WnZjbiBSek xDQnBibU5z IGRXUnBibW NnWkcgOXVZ WFJwYm1jZy BablZ1WkhN Z1lXIDVrSU hCeWIyUjEg WTNSeklIUn ZJSCBOMWNI QnZjblFnIG JXVmthV05o YkMgQnlaWE 5sWVhKaiBh Q0JoYm1RZ2 NIIEp2ZG1s a2FXNW4gSU dacGJtRnVZ MiBsaGJDQn pkWEJ3IGIz SjBJR1p2Y2 kgQnZjbWRo Ym1sNiBZWF JwYjI1eklI IGR2Y210cG JtY2cgZEc5 M1lYSmtjeS BCemIyTnBZ V3dnIGFuVn pkR2xqWlMg QmhibVFnWl hGMSBZV3hw ZEhrdVBHIE p5UGpFMExp QkogYmlBeU 1ESXhMQyBC Q2FXOHRWR1 ZqIGFHNWxJ R0Z1Ym0gOT FibU5sWkNC aCBJSEJoY2 5SdVpYIEp6 YUdsd0lIZH AgZEdnZ2RH aGxJRSBKcG JHd2dZVzVr IElFMWxiR2 x1WkcgRWdS MkYwWlhNZy BSbTkxYm1S aGRHIGx2Ym lCMGJ5Qmsg WlhabGJHOX dJRyBGdVpD QnRZVzUxIF ptRmpkSFZ5 WlMgQmhJRz V2ZG1WcyBJ SEJ5YjNSbG FXIDR0WW1G elpXUWcgUT A5V1NVUXRN VCBrZ2RtRm pZMmx1IFpT NDhZbkkrTV QgVXVJRlJv WlNCaiBiMj F3WVc1NTRv IENaY3lCdG FYTnogYVc5 dUlHbHpJSC BSdklIQnli M1pwIFpHVW dhVzV1YjMg WmhkR2wyWl NCMCBiMjlz Y3lCaGJtIF FnY21WemIz VnkgWTJWek lIUnZJRyBG a2RtRnVZMl VnIGRHaGxJ SFZ1WkcgVn ljM1JoYm1S cCBibWNnYj JZZ1ltIGx2 Ykc5bmVTQm ggYm1RZ2RH OGdZVyBOal pXeGxjbUYw IFpTQjBhR1 VnWkcgbHpZ MjkyWlhKNS BJR0Z1WkNC a1pYIFpsYk c5d2JXVnUg ZENCdlppQn VaWCBjZ2RH aGxjbUZ3IF pYVjBhV056 TGcgPT0KIC AgICAgICA8 L3NwYW4+Ci AgICAgICAg CiAgICAgIC Ag